Literature DB >> 32147886

Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression.

Xiao-Yan He1,2, Xiao-He Ren1, Yan Peng3, Jian-Ping Zhang4, Shu-Lun Ai1, Bo-Ya Liu1, Chang Xu1, Si-Xue Cheng1.   

Abstract

Effective reversal of tumor immunosuppression is of critical importance in cancer therapy. A multifunctional delivery vector that can effectively deliver CRISPR-Cas9 plasmid for β-catenin knockout to reverse tumor immunosuppression is constructed. The multi-functionalized delivery vector is decorated with aptamer-conjugated hyaluronic acid and peptide-conjugated hyaluronic acid to combine the tumor cell/nuclear targeting function of AS1411 with the cell penetrating/nuclear translocation function of TAT-NLS. Due to the significantly enhanced plasmid enrichment in malignant cell nuclei, the genome editing system can induce effective β-catenin knockout and suppress Wnt/β-catenin pathway, resulting in notably downregulated proteins involved in tumor progression and immunosuppression. Programmed death-ligand 1 (PD-L1) downregulation in edited tumor cells not only releases the PD-1/PD-L1 brake to improve the cancer killing capability of CD8+ T cells, but also enhances antitumor immune responses of immune cells. This provides a facile strategy to reverse tumor immunosuppression and to restore immunosurveillance and activate anti-tumor immunity.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer therapy; gene technology; immunosuppression; nanoparticles; programmed death-ligand 1

Mesh:

Substances:

Year:  2020        PMID: 32147886     DOI: 10.1002/adma.202000208

Source DB:  PubMed          Journal:  Adv Mater        ISSN: 0935-9648            Impact factor:   30.849


  12 in total

Review 1.  Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.

Authors:  Jihoon Kim; Susan N Thomas
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 2.  Insights into Aptamer-Drug Delivery Systems against Prostate Cancer.

Authors:  Xueni Wang; Qian Zhou; Xiaoning Li; Xia Gan; Peng Liu; Xiaotao Feng; Gang Fang; Yonghong Liu
Journal:  Molecules       Date:  2022-05-26       Impact factor: 4.927

3.  Aptamer-Functionalized Dendrimer Delivery of Plasmid-Encoding lncRNA MEG3 Enhances Gene Therapy in Castration-Resistant Prostate Cancer.

Authors:  Zongguang Tai; Jinyuan Ma; Jianing Ding; Huijun Pan; Rongrong Chai; Congcong Zhu; Zhen Cui; Zhongjian Chen; Quangang Zhu
Journal:  Int J Nanomedicine       Date:  2020-12-17

Review 4.  Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.

Authors:  Zhaoying Fu; Jim Xiang
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

5.  Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.

Authors:  Yanli Qu; Huan Wang; Hangyu Liu; Xiaohu Sun; Ji Li; Hong Yu
Journal:  Biomed Res Int       Date:  2021-04-20       Impact factor: 3.411

Review 6.  Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer.

Authors:  Huimin Zhang; Chunhong Qin; Changming An; Xiwang Zheng; Shuxin Wen; Wenjie Chen; Xianfang Liu; Zhenghua Lv; Pingchang Yang; Wei Xu; Wei Gao; Yongyan Wu
Journal:  Mol Cancer       Date:  2021-10-01       Impact factor: 27.401

Review 7.  Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.

Authors:  Yanxin Xu; Chen Chen; Yaxin Guo; Shengyun Hu; Zhenqiang Sun
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

Review 8.  Research Progress on Gene Editing Based on Nano-Drug Delivery Vectors for Tumor Therapy.

Authors:  Shiwen Xi; Yong-Guang Yang; Jian Suo; Tianmeng Sun
Journal:  Front Bioeng Biotechnol       Date:  2022-03-28

9.  Functional Tumor Targeting Nano-Systems for Reprogramming Circulating Tumor Cells with In Situ Evaluation on Therapeutic Efficiency at the Single-Cell Level.

Authors:  Xiao-He Ren; Xiao-Yan He; Chang Xu; Di Han; Si-Xue Cheng
Journal:  Adv Sci (Weinh)       Date:  2022-05-20       Impact factor: 17.521

Review 10.  Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.

Authors:  Karim Shalaby; Mustapha Aouida; Omar El-Agnaf
Journal:  Int J Mol Sci       Date:  2020-10-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.